1
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
2
|
Stosic-Grujicic S, Stojanovic I and
Nicoletti F: MIF in autoimmunity and novel therapeutic approaches.
Autoimmun Rev. 8:244–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Bloom J, Sun S and Al-Abed Y: MIF, a
controversial cytokine: A review of structural features,
challenges, and opportunities for drug development. Expert Opin
Ther Targets. 20:1463–1475. 2016. View Article : Google Scholar : PubMed/NCBI
|
4
|
Merk M, Zierow S, Leng L, Das R, Du X,
Schulte W, Fan J, Lue H, Chen Y, Xiong H, et al: The D-dopachrome
tautomerase (DDT) gene product is a cytokine and functional homolog
of macrophage migration inhibitory factor (MIF). Proc Natl Acad
Sci. 108:E577–E585. 2011. View Article : Google Scholar : PubMed/NCBI
|
5
|
Merk M, Mitchell RA, Endres S and Bucala
R: D-dopachrome tautomerase (D-DT or MIF-2): Doubling the MIF
cytokine family. Cytokine. 59:10–17. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Connelly KL, Kandane-Rathnayake R, Hoi A,
Nikpour M and Morand EF: Association of MIF, but not type I
interferon-induced chemokines, with increased disease activity in
Asian patients with systemic lupus erythematosus. Sci Rep.
6:299092016. View Article : Google Scholar : PubMed/NCBI
|
7
|
Lang T, Foote A, Lee JP, Morand EF and
Harris J: MIF: Implications in the pathoetiology of systemic lupus
erythematosus. Front Immunol. 6:5772015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Benedek G, Meza-Romero R, Jordan K, Zhang
Y, Nguyen H, Kent G, Li J, Siu E, Frazer J, Piecychna M, et al: MIF
and D-DT are potential disease severity modifiers in male MS
subjects. Proc Natl Acad Sci USA. 114:E8421–E8429. 2017. View Article : Google Scholar : PubMed/NCBI
|
9
|
Nicoletti F, Créange A, Orlikowski D,
Bolgert F, Mangano K, Metz C, Di Marco R and Al Abed Y: Macrophage
migration inhibitory factor (MIF) seems crucially involved in
Guillain-Barré syndrome and experimental allergic neuritis. J
Neuroimmunol. 168:168–174. 2005. View Article : Google Scholar : PubMed/NCBI
|
10
|
Nobre CC, de Araújo JM, Fernandes TA,
Cobucci RN, Lanza DC, Andrade VS and Fernandes JV: Macrophage
migration inhibitory factor (MIF): Biological activities and
relation with cancer. Pathol Oncol Res. 23:235–244. 2017.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Burger-Kentischer A, Finkelmeier D, Thiele
M, Schmucker J, Geiger G, Tovar GE and Bernhagen J: Binding of
JAB1/CSN5 to MIF is mediated by the MPN domain but is independent
of the JAMM motif. FEBS Lett. 579:1693–1701. 2005. View Article : Google Scholar : PubMed/NCBI
|
12
|
Babu SN, Chetal G and Kumar S: Macrophage
migration inhibitory factor: A potential marker for cancer
diagnosis and therapy. Asian Pac J Cancer Prev. 13:1737–1744. 2012.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Funamizu N, Hu C, Lacy C, Schetter A,
Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, et al:
Macrophage migration inhibitory factor induces epithelial to
mesenchymal transition, enhances tumor aggressiveness and predicts
clinical outcome in resected pancreatic ductal adenocarcinoma. Int
J Cancer. 132:785–794. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Bach JP, Deuster O, Balzer-Geldsetzer M,
Meyer B, Dodel R and Bacher M: The role of macrophage inhibitory
factor in tumorigenesis and central nervous system tumors. Cancer.
115:2031–2040. 2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Bacher M, Schrader J, Thompson N, Kuschela
K, Gemsa D, Waeber G and Schlegel J: Up-regulation of macrophage
migration inhibitory factor gene and protein expression in glial
tumor cells during hypoxic and hypoglycemic stress indicates a
critical role for angiogenesis in glioblastoma multiforme. Am J
Pathol. 162:11–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
16
|
Kitange GJ, Carlson BL, Schroeder MA,
Decker PA, Morlan BW, Wu W, Ballman KV, Giannini C and Sarkaria JN:
Expression of CD74 in high grade gliomas: A potential role in
temozolomide resistance. J Neurooncol. 100:177–186. 2010.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Wang XB, Tian XY, Li Y, Li B and Li Z:
Elevated expression of macrophage migration inhibitory factor
correlates with tumor recurrence and poor prognosis of patients
with gliomas. J Neurooncol. 106:43–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Xu S, Guo X, Gao X, Xue H, Zhang J, Guo X,
Qiu W, Zhang P and Li G: Macrophage migration inhibitory factor
enhances autophagy by regulating ROCK1 activity and contributes to
the escape of dendritic cell surveillance in glioblastoma. Int J
Oncol. 49:2105–2115. 2016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Baron N, Deuster O, Noelker C, Stüer C,
Strik H, Schaller C, Dodel R, Meyer B and Bacher M: Role of
macrophage migration inhibitory factor in primary glioblastoma
multiforme cells. J Neurosci Res. 89:711–717. 2011. View Article : Google Scholar : PubMed/NCBI
|
20
|
Wang Z, Xue Y, Wang P, Zhu J and Ma J:
MiR-608 inhibits the migration and invasion of glioma stem cells by
targeting macrophage migration inhibitory factor. Oncol Rep.
35:2733–2742. 2016. View Article : Google Scholar : PubMed/NCBI
|
21
|
Zeiner PS, Preusse C, Blank AE, Zachskorn
C, Baumgarten P, Caspary L, Braczynski AK, Weissenberger J, Bratzke
H, Reiß S, et al: MIF receptor CD74 is restricted to
microglia/macrophages, associated with a M1-polarized immune milieu
and prolonged patient survival in gliomas. Brain Pathol.
25:491–504. 2015. View Article : Google Scholar : PubMed/NCBI
|
22
|
Castro BA, Flanigan P, Jahangiri A,
Hoffman D, Chen W, Kuang R, De Lay M, Yagnik G, Wagner JR,
Mascharak S, et al: Macrophage migration inhibitory factor
downregulation: A novel mechanism of resistance to anti-angiogenic
therapy. Oncogene. 36:3749–3759. 2017. View Article : Google Scholar : PubMed/NCBI
|
23
|
Verjans E, Noetzel E, Bektas N, Schütz AK,
Lue H, Lennartz B, Hartmann A, Dahl E and Bernhagen J: Dual role of
macrophage migration inhibitory factor (MIF) in human breast
cancer. BMC Cancer. 9:2302009. View Article : Google Scholar : PubMed/NCBI
|
24
|
Jde Rosado D and Rodriguez-Sosa M:
Macrophage migration inhibitory factor (MIF): A key player in
protozoan infections. Int J Biol Sci. 7:1239–1256. 2011. View Article : Google Scholar : PubMed/NCBI
|
25
|
Gregory JL, Leech MT, David JR, Yang YH,
Dacumos A and Hickey MJ: Reduced leukocyte-endothelial cell
interactions in the inflamed microcirculation of macrophage
migration inhibitory factor-deficient mice. Arthritis Rheum.
50:3023–3034. 2004. View Article : Google Scholar : PubMed/NCBI
|
26
|
Onodera S, Nishihira J, Koyama Y, Majima
T, Aoki Y, Ichiyama H, Ishibashi T and Minami A: Macrophage
migration inhibitory factor up-regulates the expression of
interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid
arthritis patients: common transcriptional regulatory mechanism
between interleukin-8 and interleukin-1beta. Arthritis Rheum.
50:1437–1447. 2004. View Article : Google Scholar : PubMed/NCBI
|
27
|
Fingerle-Rowson G, Koch P, Bikoff R, Lin
X, Metz CN, Dhabhar FS, Meinhardt A and Bucala R: Regulation of
macrophage migration inhibitory factor expression by
glucocorticoids in vivo. Am J Pathol. 162:47–56. 2003. View Article : Google Scholar : PubMed/NCBI
|
28
|
Zhang H, Ye YL, Li MX, Ye SB, Huang WR,
Cai TT, He J, Peng JY, Duan TH, Cui J, et al: CXCL2/MIF-CXCR2
signaling promotes the recruitment of myeloid-derived suppressor
cells and is correlated with prognosis in bladder cancer. Oncogene.
36:2095–2104. 2017. View Article : Google Scholar : PubMed/NCBI
|
29
|
Yaddanapudi K, Putty K, Rendon BE, Lamont
GJ, Faughn JD, Satoskar A, Lasnik A, Eaton JW and Mitchell RA:
Control of tumor-associated macrophage alternative activation by
macrophage migration inhibitory factor. J Immunol. 190:2984–2993.
2013. View Article : Google Scholar : PubMed/NCBI
|
30
|
Krockenberger M, Dombrowski Y, Weidler C,
Ossadnik M, Hönig A, Häusler S, Voigt H, Becker JC, Leng L, Steinle
A, et al: Macrophage migration inhibitory factor contributes to the
immune escape of ovarian cancer by down-regulating NKG2D. J
Immunol. 180:7338–7348. 2008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Schindler L, Dickerhof N, Hampton MB and
Bernhagen J: Post-translational regulation of macrophage migration
inhibitory factor: Basis for functional fine-tuning. Redox Biol.
15:135–142. 2018. View Article : Google Scholar : PubMed/NCBI
|